FSM Wealth Advisors LLC Grows Position in Eli Lilly and Company (NYSE:LLY)

FSM Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 25.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,208 shares of the company’s stock after purchasing an additional 244 shares during the quarter. FSM Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $531,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Wellington Management Group LLP boosted its holdings in Eli Lilly and Company by 1.6% during the 1st quarter. Wellington Management Group LLP now owns 20,324,267 shares of the company’s stock valued at $6,979,760,000 after acquiring an additional 314,349 shares during the period. Geode Capital Management LLC boosted its holdings in Eli Lilly and Company by 1.1% during the 1st quarter. Geode Capital Management LLC now owns 14,867,424 shares of the company’s stock valued at $5,094,159,000 after acquiring an additional 159,964 shares during the period. Morgan Stanley boosted its holdings in Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after acquiring an additional 3,691,436 shares during the period. Norges Bank purchased a new position in Eli Lilly and Company during the 4th quarter valued at about $3,416,206,000. Finally, Moneta Group Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after acquiring an additional 5,440,731 shares during the period. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $630.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, September 5th. Bank of America raised their target price on Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $385.00 to $470.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 9th. Berenberg Bank raised their target price on Eli Lilly and Company from $375.00 to $500.00 in a research report on Tuesday, June 20th. Finally, Jefferies Financial Group raised Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the stock from $408.00 to $615.00 in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twenty have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $532.78.

Insider Buying and Selling

In other news, CAO Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares of the company’s stock, valued at $2,939,130.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total value of $327,906.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,378 shares in the company, valued at $2,939,130.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 34,156 shares of the company’s stock in a transaction on Tuesday, June 20th. The shares were sold at an average price of $454.08, for a total value of $15,509,556.48. Following the completion of the transaction, the insider now owns 101,387,286 shares of the company’s stock, valued at $46,037,938,826.88. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,010,309 shares of company stock valued at $21,095,701,670. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $3.52 during trading on Monday, reaching $572.14. The company’s stock had a trading volume of 1,477,363 shares, compared to its average volume of 3,030,239. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $601.84. The company has a market capitalization of $543.13 billion, a P/E ratio of 79.56, a price-to-earnings-growth ratio of 2.44 and a beta of 0.32. The business has a 50 day moving average price of $512.56 and a 200-day moving average price of $439.28.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.13. The firm had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.25 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 9.84 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date of this dividend was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio is presently 62.87%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.